Leadership team bolstered at expanding CatSci | Wales Business News

Cockwise from top left: Dr Jerome Théobald, Jaana Grüter, Rob Crook, Dr Gary Parsons, Jenn Clark and Dr Raj Gill

CatSci, a Cardiff-based contract research organization which secured investment from Keensight Capital earlier this year, has unveiled a number of appointments to its senior leadership team.

The business, formed in 2010 from a spin-out of AstraZeneca’s Catalyst Screening Facility, said the appointments, who bring decades of experience and expertise, would help its global pharmaceutical clients in meeting their chemistry, manufacturing and controls demands.

The appointments include new chief operating officer Dr Jerome Théobald, who will play a key role in supporting and propelling the growth of CatSci’s core business, and investor director Jaana Grüter who joins the CatSci board as part of the investment deal with Keensight Capital. Grüter will be influential in accelerating the business development strategy with her experience in helping firms unlock their full potential through investment.

Rob Crook has been appointed as director of chemical sciences and will be working closely with CatSci’s formulation, measurement, and material science functions while director of pharmaceutical development, Dr Gary Parsons, has notable expertise in inhaled product development and his appointment will enable CatSci to integrate API material science into dosage form design.

Elsewhere, Jenn Clark has been appointed as head of customer acquisition and will ensure that CatSci’s capabilities are aligned to the needs and expectations of its customers, while as head of scientific operations Dr Raj Gill will lead the firm’s team in the next phase of its evolution .

In June, it was announced that Keensight Capital, a private equity manager dedicated to pan-European growth buyout investments, had invested in CatSci alongside the founders, senior management and employees.

The investment will support continued growth of the core CatSci business via capability and site expansion, as well as the development of GMP capabilities and the expansion of its offering in oligonucleotide services.

Leave a Comment